# Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma

> **NCT00422786** · PHASE2 · COMPLETED · sponsor: **Thallion Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** CAP-232

## Key facts

- **NCT ID:** NCT00422786
- **Lead sponsor:** Thallion Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2008-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422786, "Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00422786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*